Osteoarthritis Shoulder Clinical Trial
Official title:
FX Shoulder Solutions Retrospective / Prospective Clinical Study
Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions and distributed by FX Shoulder Solutions.
Status | Recruiting |
Enrollment | 600 |
Est. completion date | December 30, 2032 |
Est. primary completion date | December 30, 2032 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Received an FX Shoulder Solutions replacement medical device in accordance with the Indications for Use based upon surgeons' determination and standard of care for the selected device system beginning January 1, 2018, through June 30, 2023. Exclusion Criteria: - Patient who does not meet the inclusion criteria above |
Country | Name | City | State |
---|---|---|---|
United States | OrthoArizona | Gilbert | Arizona |
United States | Advanced Orthopedics Institute | The Villages | Florida |
Lead Sponsor | Collaborator |
---|---|
FX Shoulder Solutions |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Primary Effectiveness Endpoint | The primary safety endpoint is the occurrence of any serious, device-related adverse event through 24 months of follow-up defined as an onset date before or on 730 days following the index surgery. For the primary endpoint, device-related will be defined as definite, probable, or possible relationship to the device. | 24 months | |
Primary | Number of participants who are at a minimum of 2 years postoperative follow-up based upon the following composite clinical success (CCS) of the Patient Reported Outcome Surveys and Investigator Range of Motion (ROM) assessments. | Adjusted Constant Score > 70
No continuous radiolucency or device migration/subsidence No revision surgery or removal No serious device related adverse event The Study will continue to follow patients prospectively to 10 years postoperative to track survivorship. |
10 years | |
Secondary | Adjusted Constant Score | The Constant-Murley score (CMS) is a validated 100-points scale composed of a number of individual parameters. These parameters define the level of pain and the ability to carry out the normal daily activities of the patient. The test is divided into four subscales: pain (15 points), activities of daily living (20 points), strength (25 points) and range of motion (40 points) with the subject completing the assessment prior to the Investigator completing their part of the assessment. The higher the score, the higher the quality of the function.
An Adjusted Constant score will be calculated using normalized values to account for age and gender, as based upon anatomical gender at birth. |
3, 6, 12, 24 months, 5 and 10 years. | |
Secondary | QuickDASH | QuickDASH measures an individual's ability to complete tasks, absorb forces, and severity of symptoms. The QuickDASH tool uses a 5-point Likert scale from which the patient can select an appropriate number corresponding to his/her severity level/ function level. The higher the score, the higher the function and lower pain in the patient. | 3, 6, 12, 24 months, 5 and 10 years. | |
Secondary | American Shoulder and Elbow Surgeon (ASES) | ASES is a validated patient-reported outcome which is composed of 10 functional questions and one pain VAS. The total score is of 100 maximum points and weighted evenly between pain and function | 3, 6, 12, 24 months, 5 and 10 years. | |
Secondary | Visual Analog Scale (VAS). A validated measurement of pain in a patient where 0 indicates no pain and 100 indicates severe pain. The VAS is a straight horizontal line of fixed length. | A validated measurement of pain in a patient where 0 indicates no pain and 100 indicates severe pain. The VAS is a straight horizontal line of fixed length. | 3, 6, 12, 24 months, 5 and 10 years | |
Secondary | Range of Motion | ROM - The patient performs active movements in all functional planes for the shoulder.
Includes flexion, extension, abduction, adduction and internal and external rotation. Investigator estimates the range of movement and compares the affected with the unaffected shoulder and the normal expected range. |
3, 6, 12, 24 months, 5 and 10 years. | |
Secondary | Number of Participants Who Have a Secondary Surgical Intervention (SSI) | SSI's are re-operations, revisions, and removals. | 24 months and at 5 and 10 years | |
Secondary | Device Related Adverse Events. | An adverse event that is related to the use of a device. | 24 months and at 5 and 10 years postoperative | |
Secondary | Serious Adverse Event | Led to a death,
Resulted in life threatening illness or injury* Resulted in patient hospitalization or prolongation of existing hospitalization, Resulted in patient disability or permanent damage or required intervention to prevent permanent impairment/damage Led to a congenital abnormality or birth defect |
24 months and at 5 and 10 years postoperative | |
Secondary | Serious Adverse Device Effects (SADE) | Adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event. | 24 months and at 5 and 10 years postoperative. | |
Secondary | Number of Participants with Radiographic Reviews and Assessments. | Monitor implant integrity and signs of implant loosening | 24 months, at 5 years and 10 years postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Not yet recruiting |
NCT04448106 -
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
|
Phase 2 | |
Not yet recruiting |
NCT06032416 -
DenCT Shoulder Bone Quality Evaluation
|
N/A | |
Enrolling by invitation |
NCT05067543 -
Perform Humeral System Study
|
||
Completed |
NCT04641546 -
Effectiveness of Occupation-Based Intervention Compared With Therapeutic Exercise for Older Adults With Shoulder OA.
|
N/A | |
Recruiting |
NCT05868148 -
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
|
||
Completed |
NCT03431857 -
Multi Centre Study on TESS V2 Shoulder System
|
||
Recruiting |
NCT05861960 -
Endogenous Pain Modulation Study
|
||
Recruiting |
NCT06078865 -
FX Shoulder Prospective Clinical Study
|
||
Recruiting |
NCT04929951 -
The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis
|
Phase 1 | |
Recruiting |
NCT04968405 -
Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty
|
N/A | |
Enrolling by invitation |
NCT05500066 -
AEQUALIS™ FLEX REVIVE™ Study (REVIVE)
|
||
Active, not recruiting |
NCT05002959 -
TESS V3 Modular Total Shoulder System PMCF
|
||
Active, not recruiting |
NCT06171542 -
Efficacy of a Single Image Guided Injection of CTM for Glenohumeral Arthritis
|
Phase 1 | |
Recruiting |
NCT05487274 -
TSA v RSA in Osteoarthritic Shoulders With Greater Than 15 Degrees of Retroversion
|
N/A |